Phillies’ Johan Rojas suspended 80 games for failed drug test
(*80*)
NEW YORK — Philadelphia Phillies outfielder Johan Rojas was suspended for the primary 80 games of the season by Major League Baseball on Monday following a optimistic test for the performance-enhancing substance Boldenone.
Rojas’ suspension was introduced after a grievance filed by the gamers’ affiliation interesting the self-discipline was denied by unbiased arbitrator Martin F. Scheinman.
Barring rainouts, Rojas can be eligible to play for the Phillies on June 25. He would lose $395,305 in wage from his contract, which pays at a price of $803,500 whereas within the main leagues and $321,826 whereas within the minors. If there aren’t any postponements, the suspension can be over 92 days of the 187-day season.
He is ineligible to play within the 2026 postseason.
“The Phillies fully support Major League Baseball’s Joint Prevention and Treatment Program and are disappointed to hear today’s news of Johan’s violation,” the group said in a statement.
Rojas, 25, hit .224 with one homer, 18 RBIs and 12 stolen bases for the Phillies final season. He was demoted to Triple-A Lehigh Valley on Aug. 1 and did not play for Philadelphia through the the rest of the season. Rojas was 3-for-15 with one RBI for the Phillies throughout spring coaching this yr.
He has a .252 profession common with six homers, 73 RBIs and 51 stolen bases over 250 games.
Rojas was slated to play for the Dominican Republic’s World Baseball Classic roster however was dropped forward of the event.
He is the sixth participant disciplined this yr for a drug violation, the third underneath the foremost league settlement.
atlanta outfielder Jurickson Profar was suspended for the complete season on March 3 after testing optimistic for exogenous testosterone and its metabolites. The failed test was Profar’s second offense underneath the drug guidelines.
Free agent outfielder Max Kepler was banned for 80 games on Jan. 9 after a optimistic test for Epitrenbolone.
The Associated Press contributed to this report.
